AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01173224
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Trial: NCT00492752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (orally) twice daily
Trial: NCT01377779
Drug: Oxiplex/AP gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine application of Intercoat following hysteroscopy
Trial: NCT01377779
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intrauterine application of Intercoat following hysteroscopy
Trial: NCT02502500
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02502500
Drug: AKB-6548
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00867399
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm for details
Trial: NCT03749252
Drug: P03277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
Trial: NCT03538327
Drug: Silybin
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
Trial: NCT01339247
Drug: Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Trial: NCT01339247
Drug: Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Trial: NCT01223430
Drug: Si-Ni-Tang/ Placebo of Si-Ni-Tang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
Trial: NCT00794157
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT03632733
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline cream
Trial: NCT03632733
Drug: Tetracycline and Clotrimazole
RxNorm normalized name: tetracycline and nystatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cream
Trial: NCT02521545
Drug: BIIB061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT01332903
Drug: [14C] AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 120 mg oral dose administered on Day 1
Trial: NCT02404259
Drug: TDF (Tenofovir)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04036890
Drug: 2% minocycline hydrochloride controlled-delivery system (MHS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
Trial: NCT04036890
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is the same gel as MHS but without active ingredient minocycline hydrochloride.
Trial: NCT00836056
Drug: Clindamycin 300 mg capsule
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 300 mg
Trial: NCT02488564
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
Trial: NCT01516346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
Trial: NCT01632995
Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
Trial: NCT04486950
Drug: TAK-951 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 placebo-matching intravenous infusion.
Trial: NCT00401375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
Trial: NCT04523220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration in the same manner as Osocimab.
Trial: NCT02605824
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is a placebo agent.
Trial: NCT00796653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Trial: NCT03699176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT00606203
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00081159
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
Trial: NCT00081159
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
Trial: NCT01940341
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet administered orally once daily
Trial: NCT01509196
Drug: HIP0901 / Lipidilsupra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
Trial: NCT02688023
Drug: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
Trial: NCT02864368
Drug: Tetanus-Diphtheria booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
Trial: NCT02864368
Drug: Tetanus Pre-Conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
Trial: NCT01217021
Drug: [18F] MNI-558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
Trial: NCT02030041
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin in a dose of 40 mg will be provided to the study participants
Trial: NCT02030041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided to the study participants
Trial: NCT00003105
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02947152
Drug: HKT288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadherin-6-targeting antibody-drug conjugate for intravenous administration
Trial: NCT03402984
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
Trial: NCT01182246
Drug: AXP107-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa.
Trial: NCT04158076
Drug: Ezetimibe/Rosuvastatin
RxNorm normalized name: EZETIMIBE/ROSUVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT01353040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration
Trial: NCT00616122
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03283826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to ATA188
Trial: NCT02354560
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
Trial: NCT00002831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
Trial: NCT00002831
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
Trial: NCT02122198
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Climara transdermal patch 0.075mg/day applied weekly months 6-9
Trial: NCT02122198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03295162
Drug: Melatonin 10 mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
Trial: NCT00147498
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at a dose of 5 mg BID for 6 weeks
Trial: NCT00147498
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at a dose of 15 mg BID for 6 weeks
Trial: NCT00147498
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg BID for 6 weeks
Trial: NCT02447874
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours
Trial: NCT02447874
Drug: Arginine (Loading)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Trial: NCT02447874
Drug: Arginine (Continuous)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
Trial: NCT04542356
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
Trial: NCT03331289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
Trial: NCT01963728
Drug: Insulin, Isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dosing based on fasting morning glucose levels
Trial: NCT00931697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-encapsulated placebo to maintain blinding
Trial: NCT02004197
Drug: Quadruple Allopathic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02004197
Drug: Pylorex plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03100344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)
Trial: NCT04216459
Drug: intravenous vitamin C plus thiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
Trial: NCT04480762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of the SHR-1703
Trial: NCT03202459
Drug: Group C - placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
Trial: NCT00349843
Drug: Marketed soft lens multipurpose disinfection regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00804960
Drug: Std IVF Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
Trial: NCT03797872
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate up to 25mg/week as tolerated po or sc
Trial: NCT01411202
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
Trial: NCT03139812
Drug: Daily irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
Trial: NCT03889314
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Statin Therapy
Trial: NCT01750385
Drug: no antibiotic prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
Trial: NCT01750385
Drug: second-generation cephalosporin
RxNorm normalized name: Second-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
Trial: NCT03670212
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
Trial: NCT03670212
Drug: Lactose Monohydrate Powder
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
Trial: NCT02081534
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1722, oral tablet
Trial: NCT02081534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid, double dummy technique
Trial: NCT00535561
Drug: Ferrous sulfate plus levothyroxine
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous succinate (DB14489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
Trial: NCT03405454
Drug: standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy treatment will be administered as per local institutional guidelines
Trial: NCT02881437
Drug: IgHy10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub Cutaneous IgHy10 administration
Trial: NCT00403234
Drug: Placebo BTDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
Trial: NCT03303950
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00485394
Drug: vehicle placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT-551 0% ophthalmic solution, 2 drops 4 times daily
Trial: NCT01888822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic placebo infusion before elective laparoscopic cholecystectomy
Trial: NCT00854659
Drug: ABT-102
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID tablets, 7 days of treatment
Trial: NCT00854659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID tablets, 7 days of treatment
Trial: NCT01032304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule twice a day
Trial: NCT00639483
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Trial: NCT00639483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Trial: NCT03577730
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
Trial: NCT02289222
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
Trial: NCT00834067
Drug: UNIRETIC® 15/25 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 15/25 mg
Trial: NCT01725555
Drug: Fed treatment: AXL1717
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01135498
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose